Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
about
Overcoming Hypoxia-Mediated Tumor Progression: Combinatorial Approaches Targeting pH Regulation, Angiogenesis and Immune DysfunctionThe Impact of Chemotherapy, Radiation and Epigenetic Modifiers in Cancer Cell Expression of Immune Inhibitory and Stimulatory Molecules and Anti-Tumor EfficacyNegative influence of programmed death-1-ligands on the survival of esophageal cancer patients treated with chemotherapyPD1 blockade enhances cytotoxicity of in vitro expanded natural killer cells towards myeloma cells.Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application.Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer.Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysisAssociation between B7-H1 and cervical cancer: B7-H1 impairs the immune response in human cervical cancer cells.Carboplatin and programmed death-ligand 1 blockade synergistically produce a similar antitumor effect to carboplatin alone in murine ID8 ovarian cancer model.Clinical evaluation of macrophages in cancer: role in treatment, modulation and challenges.Axl inhibition induces the antitumor immune response which can be further potentiated by PD-1 blockade in the mouse cancer models.Depletion of tumor-associated macrophages switches the epigenetic profile of pancreatic cancer infiltrating T cells and restores their anti-tumor phenotype.DOX/IL-2/IFN-γ co-loaded thermo-sensitive polypeptide hydrogel for efficient melanoma treatment.
P2860
Q26749333-C5C05137-2AEC-4EDC-A1EA-B3C36023BCF2Q28076473-952E0F07-B2F5-4A76-B24B-CA5DE932E671Q37142435-F65902D0-208A-484F-9B25-63598C7E337BQ37565475-5649C377-D29D-4737-8FB2-165F24E3CDD4Q38770458-1ED2B63A-D2F7-471F-96AA-B77CB3FDC1F9Q39402079-61FB60A0-BD71-4EF4-8253-8E8BE402B162Q41590737-29D617D9-9345-4578-9C38-AD6153E417D5Q43480316-72E5B03A-907F-406F-95F9-D93E8A40C409Q47820348-CC8F1D26-A319-4168-A543-422C9082C35BQ48290538-D0394152-952C-40D4-B9E2-A3DC0A2E1E2FQ49737040-3B27B06D-E3B9-4430-BC31-18754AEEC79CQ50545391-FC48355A-B6E4-4E42-A018-7F6B8E919EE2Q55241239-CCCCADFC-E33D-4A00-949B-2E0F83154B03
P2860
Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Combined Trabectedin and anti- ...... urine model of ovarian cancer.
@ast
Combined Trabectedin and anti- ...... urine model of ovarian cancer.
@en
type
label
Combined Trabectedin and anti- ...... urine model of ovarian cancer.
@ast
Combined Trabectedin and anti- ...... urine model of ovarian cancer.
@en
prefLabel
Combined Trabectedin and anti- ...... urine model of ovarian cancer.
@ast
Combined Trabectedin and anti- ...... urine model of ovarian cancer.
@en
P2093
P2860
P1476
Combined Trabectedin and anti- ...... urine model of ovarian cancer.
@en
P2093
Fandong Meng
Haolin Wang
Shulan Zhang
Zhiqiang Guo
P2860
P2888
P356
10.1186/S12967-015-0613-Y
P577
2015-07-29T00:00:00Z
P5875
P6179
1007665916